Stage IV survivor of pancreatic cancer diagnosed in June 2012. Underwent Whipple procedure with portal vein resection followed by aggressive chemotherapy and the first US patient enrolled in the PARP-1 inhibitor trial RucaPANC at Penn Medicine.